LENZ LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. (LENZ) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 2% planned / 98% discretionary
Largest single sale: $3.9M.
Where they traded
Last open-market purchase: March 27, 2026 , by Chevallard Daniel R. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary | Buy | 28,089 | $8.95 | $251.4K | 77,289 | |
| Chevallard Daniel R. | Chief Financial Officer | Buy | 7,500 | $8.57 | $64.3K | 12,886 | |
| George Jeffrey P. | Director | Buy | 5,592 | $8.92 | $49.9K | 5,592 | |
| Olsson Shawn 2 fills | Chief Commercial Officer | Sell 10b5-1 | 10,000 | $26.10 | $261.0K | 10,521 −48.7% of holding | |
| MCCOLLUM JAMES W | Director | Buy | 10,500 | $22.79 | $239.3K | 10,500 | |
| Chevallard Daniel R. 2 fills | Chief Financial Officer | Buy | 2,198 | $22.76 | $50.0K | 5,386 | |
| 6 fills | Sell | 224,974 | $46.01 | $10.4M | 1,133,842 −16.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.